

For Immediate Release

**Alembic Pharmaceuticals Limited
Consolidated Results for Quarter / Year ended
31.03.2011**

Editors Synopsis

- **For the quarter net sales up 30% at Rs 297.73 crores against Rs. 228.77 crores in corresponding quarter last year**
- **For Q4FY11 Profit before tax at Rs. 13.03 crores and after Tax for at Rs. 10.28 crores**
- **For year ended March 11, net sales up by 17% at Rs. 1206.64 crores against Rs. 1034.97 crores last year.**
- **Profit before tax at Rs. 106.85 crores**
- **Net Profit after tax for full year Rs 85.39 crores**

Vadodara, 2nd May 2011

Alembic Pharmaceuticals Limited publishes its results for the first time after the approval of demerger scheme by High court.

Alembic Pharmaceuticals Limited, the pharmaceutical major, today reported a 30% increase in revenues to Rs 297.73 crores for the quarter ended 31st March 2011, compared to Rs 228.77 crores in the corresponding quarter last year.

Alembic Pharmaceutical registered operating profit of Rs. 27.22 crores.

The Company posted net profit of Rs. 10.28 crores for the quarter ended March 2011 and Rs. 85.39 crores for full year 2010-11.

Domestic Formulation Business

The domestic formulations posted sales of Rs. 157.41 crores against Rs. 131.43 crores registering healthy 20% growth over the corresponding quarter of the previous year.

Full year numbers were also encouraging since company posted 19% growth in sales at Rs. 693.43 crores against Rs. 584.90 crores in previous year..

Alembic has maintained market share of 1.78%.

The company continues to make investment in the domestic branded business, particularly with the newer specialty segments. The Company has also renewed its focus on penetrating rural segment.

Alembic has five brands in the list of top 300 brands of the industry i.e. 'Azithral' , 'Roxid', 'Althrocin', 'Zeet' and 'Wikoryl'.

International Generics

International generics grew by 147% to Rs. 55.29 crores from Rs. 22.35 crores over corresponding quarter last year. On full year basis sales grew by robust 70% to Rs. 173.77 crores from Rs. 102.00 crores.

API

For the quarter, Domestic API sales recorded a growth of 338% at Rs. 32.13 crores against Rs. 7.33 crores of PY. Export API recorded sales of Rs. 34.20 crores against Rs. 46.56 crores.

For the full year, Alembic has filed 38 ANDAs (Abbreviated New Drug Application) and 53 DMFs (Drug Master File). The Company has received approval for 15 ANDA's cumulatively.

Summary of total revenue (consolidated) for the quarter is as under:

(Rs. in Lacs)

Particulars			
	Q4FY11	Q4FY10	% Change
Formulation			
Domestic	15741	13143	20%
International Branded	1370	1726	(-)20%
International Generics	5529	2235	147%
API			
Domestic	3213	733	338%
International ROW	1965	1491	32%
International Regulatory	1455	3165	(-)54%
Export Incentives	500	384	30%
Total	29,773	22,877	30%

Summary of total revenue (consolidated) for the full year is as under:

(Rs. in Lacs)

Particulars			
	FY 10-11	FY 09-10	% Change
Formulation			
Domestic	69,343	58,490	19%
International Branded	5,015	4,576	10%
International Generics	17,377	10,200	70%
API			
Domestic	9,451	3,260	190%
International ROW	8,181	4,561	79%
International Regulatory	9,809	21,400	(-)54%
Export Incentives	1,487	1,010	28%
Total	120,664	103,497	17%

The previous years figures are approx. and unaudited numbers of relevant businesses which were then part of Alembic Limited. These are given just for comparison purpose

The Profit break-up for the quarter:
(Rs. in Lacs)

Particulars	Q4FY11	FY10-11
Operating Income	2723	16033
Profit Before Tax	1303	10685
Net Profit after Tax	1028	8539

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in Macrolides segment of anti-infective drugs in India.

Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

For more information:

Alembic Limited

Mitanshu Shah / Sanjay Bhatt

0265 – 3007630 / 3007853

mitanshu.shah@alembic.co.in / sanjay.bhatt@alembic.co.in